208 related articles for article (PubMed ID: 35658217)
1. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
[TBL] [Abstract][Full Text] [Related]
2. Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study.
Marin RC; Bungau SG; Tit DM; Negru PA; Radu AF; Moleriu RD
Biomed Pharmacother; 2023 May; 161():114427. PubMed ID: 36822019
[TBL] [Abstract][Full Text] [Related]
3. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
[TBL] [Abstract][Full Text] [Related]
4. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Gori A; Antinori A; Vergori A; Cossu MV; Menzaghi B; Sterrantino G; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):290-294. PubMed ID: 32101882
[TBL] [Abstract][Full Text] [Related]
6. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
[No Abstract] [Full Text] [Related]
7. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
Sahloff EG; Duggan JM
Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
[TBL] [Abstract][Full Text] [Related]
9. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
10. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
11. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
12. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
[TBL] [Abstract][Full Text] [Related]
13. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
15. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
[TBL] [Abstract][Full Text] [Related]
16. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
17. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
Roberts O; Khoo S; Owen A; Siccardi M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
[TBL] [Abstract][Full Text] [Related]
18. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
[TBL] [Abstract][Full Text] [Related]
19. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Squillace N; Bozzi G; Colella E; Gori A; Bandera A
Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
[TBL] [Abstract][Full Text] [Related]
20. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
